Product Description
Mechanisms of Action: Osteoclast Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gador
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Pain|Low Back Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2015-004269-96 |
2015-004269-96 | P2 |
Active, not recruiting |
Low Back Pain|Chronic Pain |
2017-08-24 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|